Advance Nanotech Expands Senior Management Team; Nanotechnology Leader Appoints Peter Gammel To Head Electronics Group.NEW YORK New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of -- Advance Nanotech, Inc., (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:AVNA AVNA Atrioventricular Node Artery .OB - News), the premier provider of financing and support services support services Psychology Non-health care-related ancillary services–eg, transportation, financial aid, support groups, homemaker services, respite services, and other services to drive the commercialization of nanotechnology discoveries, today announced the appointment of Peter Gammel to the position of Senior Vice President, Electronics. Dr. Gammel will be responsible for managing all of the firm's partnerships and investments in electronics-related nanotechnology companies. He will report directly to Advance Nanotech CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Magnus Gittins. "We are excited to have Dr. Gammel join our team," said Mr. Gittins. "He brings a wealth of expertise in the fields of optoelectromechanical, wireless, and MEMS (MicroElectroMechanical Systems) Tiny mechanical devices that are built onto semiconductor chips and are measured in micrometers. In the research labs since the 1980s, MEMS devices began to materialize as commercial products in the mid-1990s. technologies. Dr. Gammel's deep product development experience with industry-leading innovators like Lucent and MIT MIT - Massachusetts Institute of Technology makes him uniquely qualified to help our portfolio companies bring new technologies from the laboratory to commercialization." Prior to joining Advance Nanotech, Dr. Gammel held the position of CTO (Chief Technical Officer) The executive responsible for the technical direction of an organization. See CIO and salary survey. of Agere Systems' Analog Products Division where he was responsible for the technology and roadmaps for high frequency power transistor products. Dr. Gammel also served as the Director of Materials Physics Research at Lucent Technologies and in several leadership positions at AT&T Bell Laboratories. Before entering the corporate world, Dr. Gammel conducted research at several leading universities, including Cornell University Cornell University, mainly at Ithaca, N.Y.; with land-grant, state, and private support; coeducational; chartered 1865, opened 1868. It was named for Ezra Cornell, who donated $500,000 and a tract of land. With the help of state senator Andrew D. , M.I.T. and Washington University Washington University, at St. Louis, Mo.; coeducational; est. as Eliot Seminary 1853, opened 1854, renamed 1857. It has a well-known medical school and school of social work as well as research centers for radiology, space studies, engineering computing, and the . He holds a PhD in physics from Cornell and two BS degrees from M.I.T., in Physics and Mathematics. Dr. Gammel is responsible for approximately 50 patent filings and more than 200 publications through his work with Agere, Lucent, AT&T Bell Labs, Cornell University, and M.I.T. Advance Nanotech is currently funding 18 portfolio companies in the electronics, biopharma, and materials industries. The firm provides services ranging from funding, to human capital and research equipment essential to ensuring that the most promising companies can accelerate the path to rapid commercialization. In this way, investor exposure to any particular technology is mitigated with Advance Nanotech retaining the option to increase investment in those technologies that successfully mature. Dr. Gammel will be responsible for overseeing the firm's electronics-focused investments. About Advance Nanotech, Inc. Advance Nanotech Inc. is dedicated to ensuring nanotechnology discoveries reach maximum market potential through successful commercialization. Advance is the trusted guide to commercial success for nanotech entrepreneurs spanning the globe, partnering with leading universities to provide scientists and researchers with mission critical infrastructure support to transform their discoveries to marketable solutions. The organization provides a range of services and support including financing, leadership assets and counsel on intellectual property, licensing and regulatory issues. With a portfolio of nearly 20 companies developing technologies which offer potentially breakthrough nanotechnology discoveries in the electronics, biopharma and materials sectors, Advance's goal is to transform the potential for nanotechnology discoveries into innovative products that further evolve existing industries and enable new markets. This document contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech's dependence on third parties and partners; and those risks described Advance Nanotech 's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements. Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion